The effect of using Cannabidiol on the severity of spasticity in MS patients with gait disorders - Trial IRCT20220815055709N1
Access comprehensive clinical trial information for IRCT20220815055709N1 through Pure Global AI's free database. This Phase 3 trial is sponsored by Khosro Medisa Teb Company and is currently Completed. The study focuses on Multiple sclerosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Iranian Registry Of Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
IRCT20220815055709N1
Phase 3
Completed
drug
Trial Details
Iranian Registry Of Clinical Trial • IRCT20220815055709N1
The effect of using Cannabidiol on the severity of spasticity in MS patients with gait disorders
Effects of oral cannabidiol (CBD) usage on variable severity of spasticity in multiple sclerosis patients with gait problem caused by their spasticity. A Double-Blind Randomised Controlled Trial
Study Focus
Sponsor & Location
Khosro Medisa Teb Company
Iran
Timeline & Enrollment
Phase 3
Jan 21, 2023
N/A
ICD-10 Classifications
Multiple sclerosis
Progressive systemic sclerosis
Systemic sclerosis
Systemic sclerosis, unspecified
Diffuse sclerosis
Data Source
Iranian Registry Of Clinical Trial
IRCT20220815055709N1
Non-Device Trial